Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling

Uh-oh. It was easy for Roche to brush off the failure of a high-risk bet on its anti-TIGIT drug tiragolumab in March. The indication was always a long shot. Now, though, tiragolumab has flunked a second phase 3 test, failing to improve on the progression-free survival (PFS) achieved by Tecentriq alone in patients with non-small cell lung cancer (NSCLC).